PHARMA LITERATI

A very Happy New Year to the readers of the blog. As a part of the Pharma Innovation Yatra 2017, we would be reaching pharmacy institutes all over India.  So 2017 would be the year of going live, setting new trends for the blog. We at Pharma Literati would continue with many of the current activities and would be launching exciting new stuff for the readers. Get in touch with us via email pharmaliterati@gmail.com to know more about the creative thinking workshop and the Pharma Innovation Yatra.  Starting from 15th January 2017. 

Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed. We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at  pharmaliterati@gmail.com Invention Application Number Inventors Institute 2 nd December 2016 A controlled release formulation and a method of preparation thereof 1498/DEL/2015A 1) Mohanty, Sanat IIT, Delhi Biphenyl analogs and their derivatives as antifungal agents 1673/DEL/2015A 1) Megha Rikhi 2) Shanu Hoda 3) Swati Kaushik 4) Seema Bhatnagar 5) V. Pooja 6) Anjali Soni 7) B. Jayaram Amity University, Noida 9 t

The blue highlighted events are updated over the last post. Events Date Place Sponsor 1st Pharma Innovation Yatra 2017 Throughout 2017 Across India Pharma Literati and FlexiTutr. Seminar on ‘Facility qualification for oral Solid formulation unit’. 11 th Jan. 2017 NIPER, Mohali Small and Medium Pharmaceutical Industry Centre 2 nd  International Conference on Clinical Pharmacy - CPCON Catalyzing Changes in Healthcare Practice 20 th  - 21 st   Jan. 2017 Manipal, Karnataka Manipal College of Pharmaceutical Sciences. XXI quality improvement program on, “Trends in Pharmaceutical Sciences” 30 th Jan - 10 th Feb. 2017 DIPSAR, New Delhi. AICTE 8th International Symposium on Current Trends in Healthcare "Advances in New Drug Discovery And Development" 2 nd  - 4 th  Feb. 2017

Dive Brief: • Amid intense scrutiny on pharmaceutical innovation and drug value, the industry saw far fewer novel drugs approved by the Food and Drug Administration in 2016 than in years past. • Only 22 new molecular entities (NME) were approved this year, down substantially from the two-decade high of 45 last year. • Adding to that poor showing, a new report published earlier this month put the projected returns from pharma's late-stage drug pipeline at a measly 3.7%. Taken together with the falling NME approvals, the report raises questions about the efficiency and success of pharma R&D. Dive Insight: The report, compiled by the consulting and accounting firm Deloitte , paints a picture of an industry caught between rising R&D costs on one hand and falling average projected peak sales on the other. According to Deloitte, the cost to usher a drug from discovery all the way through launch - an elusive and usually controversial figure - stabilized at a lit

The Cabinet on Wednesday approved the sale of surplus land of ailing state-owned pharma companies Indian Drugs & Pharmaceuticals Limited ( IDPL ), Rajasthan Drugs & Pharmaceuticals Limited ( RDPL ), and Bengal Chemicals & Pharmaceuticals Limited ( BCPL ) to pay off their existing liabilities. While IDPL and RDPL will be closed down after settling their current liabilities, the Union government will explore the option to undertake a strategic sale of BCPL and Hindustan Antibiotics Limited at a later stage, according to an official statement. “ In this way, the national assets would be utilized in the best national interest. The sale (of land) would be through open competitive bidding to government agencies and the outstanding liabilities will be met from the sale proceeds .” The public sector firms have also been asked to implement a Voluntary Retirement Scheme and Voluntary Separation Scheme for their employees. The remaining part of their land assets wil

The Pharmacy Council of India (PCI) has instructed all the pharmacy colleges to implement the newly introduced syllabus for B. Pharm and M. Pharm courses and also submit compliance of implementation of the same and regulations to PCI by August 1, 2017 . The council has instructed the colleges running the pharmacy courses to strictly follow the statutory provisions contained in the rules for B. Pharm and M. Pharm courses for approval under section 12(1) and 12(2) of the Pharmacy Act, 1948. The further extension of approval of pharmacy institutions under section 12(1) and of the universities under section 12(2) of the Pharmacy Act, 1948 shall depend on the implementation of the B Pharm and M Pharm courses of study and syllabus prescribed by the PCI. The PCI has recently come up with the final notification on M Pharm and B Pharm syllabus with an aim to make the syllabus of the said courses more of industry oriented by introducing uniform syllabus for the courses across the

The first phase of prestigious Pharma City project on the outskirts of Hyderabad is moving at a faster pace and is expected to be completed by end of 2018. As part of this, the state government of Telangana has already acquired 5640 acres of land out of required 15,000 acres and had already started building basic infrastructure facilities like roads, drainage and common effluent treatment plants. “ We are planning to build a chain-type Pharma City, which is designed as a self contained facility with residential townships for people working there in addition to a pharmaceutical university and a research centre among other things ,” informed K. Taraka Rama Rao, minister for industries and information technology. Conscious about environmental concerns, the state government of Telangana is encouraging the Pharma City project to be developed as a zero-liquid discharge facility while adequate precautions will be taken to make it environmentally safe and pollution free. “ Pharma